Market News AIOpen the app

MBRX stock news · Moleculin Biotech, Inc.

Stories about Moleculin Biotech, Inc. (MBRX) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for MBRX

Follow Moleculin Biotech, Inc. (MBRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MBRX
Free on the App Store and Google Play, or on the web.
  1. Sep 28, 2026, 7:04 AM ET · Market

    Moleculin Biotech, Inc. shares news about a study on Annamycin's heart safety.

    Neutral

    Moleculin announced a peer-reviewed review of Annamycin's heart safety in 90 patients. The filing gives no results, so this does not change the company's outlook.

  2. Sep 25, 2026, 1:08 PM ET · Market

    Moleculin Biotech, Inc. shares new research showing its drug Annamycin fights pancreatic cancer.

    Neutral

    Moleculin shared early lab findings about its pancreatic cancer drug, but they show no patient benefit. A recent warning of possible Nasdaq removal leaves the company's outlook mixed.

  3. Sep 21, 2026, 1:30 PM ET · Market

    On Monday, 12 health care stocks changed a lot in price during trading.

    Neutral

    Moleculin Biotech declined 25.93% to $0.57, though the article gives only the intraday move and market value, not firm-level news.

  4. Sep 18, 2026, 5:04 PM ET · Market

    Moleculin Biotech, Inc. has been told it might be removed from Nasdaq because its stock price is too low.

    Bad for MBRX

    Nasdaq says Moleculin failed the $1 minimum bid rule and is not eligible for the 180-day cure, increasing delisting risk for the stock.

  5. Sep 11, 2026, 5:33 PM ET · Market

    12 health care stocks changed a lot during Friday's after-hours trading.

    Good for MBRX

    Moleculin Biotech shares rose 4.88% to $0.75 after hours, a positive intraday price change.